维基百科

C-26

C-26是在1975年建系的小鼠杂种瘤（英语：Hybridoma technology）细胞系。

历史

编辑

最初于1975年分离自一个6个月大的雌性Balb/c实验小鼠的结肠杂种瘤组织，研究人员通过在肠上单次应用N-亚硝基-N-甲基尿素（英语：N-Nitroso-N-methylurea）诱导小鼠形成肿瘤来建立C-26肿瘤细胞模型[1]，直至1988年才正式在体外培养中建立C-26细胞系[2]，并且发现C-26细胞具有很高的致瘤性及低的转移趋势，而接种C-26细胞的小鼠出现高死亡率的情况[2]。1990年，有研究人员发现在食物摄入量不变的情况下，进行体内植入C-26细胞的小鼠普遍会减轻体重，同时出现低血糖和分泌过多皮质类固醇的现象。C-26细胞不仅会使肝功能出现紊乱，还会引致脂肪、骨骼及肌肉组织的损失，因此是研究恶病体质潜在机制的合适模型。值得注意的是C-26细胞诱导的恶病体质会因接种部位的不同而存在差异[3]。近年，有研究人员在小鼠的侧面或背部植入C-26肿瘤细胞的固体片段至体内[4]。

科研用途

编辑

癌症方面

编辑

目前已将C-26模型用于研究癌症的自然史和抗肿瘤治疗。例如研究MMP抑制剂的功效[5]、显示肿瘤部位的血管生成素利用率降低会阻碍新血管的生成，从而限制肿瘤的生长和转移[6]。不少研究项目透过将C-26细胞注射到小鼠体内来探究各种当时未解决的问题，例如CXCR3的拮抗作用对抗癌细胞向靶器官发展的潜力[7]、糖皮质激素脂质体制剂的抗肿瘤作用[8]、植入C-26细胞的小鼠接受几种抗肿瘤药物时发生的作用[9]，以及间质内激光凝固与阿霉素联合治疗的效果[10]。此外，C-26细胞同时已应用于证明白介素18（英语：Interleukin 18）[11]、白介素27（英语：Interleukin 27）[12]和趋化因子CCL21（英语：CCL21）/SLC的抗肿瘤作用[13]。

参考资料

编辑
  1. ^ Corbett, TH; Griswold DP, Jr; Roberts, BJ; Peckham, JC; Schabel FM, Jr. Tumor induction relationships in development of transplantable cancers of the colon in mice for chemotherapy assays, with a note on carcinogen structure.. Cancer research. 1975-09, 35 (9): 2434–9 [2019-12-11]. PMID 1149045. 
  2. ^ 2.0 2.1 Allison, DC; Ridolpho, PF; Anderson, S; Bose, K. Variations in the [3H]thymidine labeling of S-phase cells in solid mouse tumors.. Cancer research. 1985-12, 45 (12 Pt 1): 6010–6 [2019-12-11]. PMID 4063961. 
  3. ^ Tanaka, Y; Eda, H; Tanaka, T; Udagawa, T; Ishikawa, T; Horii, I; Ishitsuka, H; Kataoka, T; Taguchi, T. Experimental cancer cachexia induced by transplantable colon 26 adenocarcinoma in mice.. Cancer research. 1990-04-15, 50 (8): 2290–5 [2019-12-11]. PMID 2317817. 
  4. ^ Samuels, SE; McLaren, TA; Knowles, AL; Stewart, SA; Madelmont, JC; Attaix, D. Liver protein synthesis stays elevated after chemotherapy in tumour-bearing mice.. Cancer letters. 2006-07-28, 239 (1): 78–83 [2019-12-11]. PMID 16140458. doi:10.1016/j.canlet.2005.07.026. 
  5. ^ Lozonschi, L; Sunamura, M; Kobari, M; Egawa, S; Ding, L; Matsuno, S. Controlling tumor angiogenesis and metastasis of C26 murine colon adenocarcinoma by a new matrix metalloproteinase inhibitor, KB-R7785, in two tumor models.. Cancer research. 1999-03-15, 59 (6): 1252–8 [2019-12-11]. PMID 10096556. 
  6. ^ Melani, C; Stoppacciaro, A; Foroni, C; Felicetti, F; Caré, A; Colombo, MP. Angiopoietin decoy secreted at tumor site impairs tumor growth and metastases by inducing local inflammation and altering neoangiogenesis.. Cancer immunology, immunotherapy : CII. 2004-07, 53 (7): 600–8 [2019-12-11]. PMID 14985859. doi:10.1007/s00262-004-0500-5. 
  7. ^ Cambien, B; Karimdjee, BF; Richard-Fiardo, P; Bziouech, H; Barthel, R; Millet, MA; Martini, V; Birnbaum, D; Scoazec, JY; Abello, J; Al Saati, T; Johnson, MG; Sullivan, TJ; Medina, JC; Collins, TL; Schmid-Alliana, A; Schmid-Antomarchi, H. Organ-specific inhibition of metastatic colon carcinoma by CXCR3 antagonism.. British journal of cancer. 2009-06-02, 100 (11): 1755–64 [2019-12-11]. PMID 19436305. doi:10.1038/sj.bjc.6605078. 
  8. ^ Schiffelers, RM; Banciu, M; Metselaar, JM; Storm, G. Therapeutic application of long-circulating liposomal glucocorticoids in auto-immune diseases and cancer.. Journal of liposome research. 2006, 16 (3): 185–94 [2019-12-11]. PMID 16952873. doi:10.1080/08982100600851029. 
  9. ^ Lupu, CM; Eisenbach, C; Kuefner, MA; Schmidt, J; Lupu, AD; Stremmel, W; Encke, J. An orthotopic colon cancer model for studying the B7-H3 antitumor effect in vivo.. Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract. 2006-05, 10 (5): 635–45 [2019-12-11]. PMID 16713537. doi:10.1007/bf03239969. 
  10. ^ Veenendaal, LM; van Hillegersberg, R; Smakman, N; van der Bilt, JD; van Diest, PJ; Kranenburg, O; Borel Rinkes, IH. Synergistic effect of interstitial laser coagulation and doxorubicin in a murine tumor recurrence model of solitary colorectal liver metastasis.. Annals of surgical oncology. 2006-02, 13 (2): 168–75 [2019-12-11]. PMID 16424982. doi:10.1245/ASO.2006.03.076. 
  11. ^ Leng, J; Zhang, L; Yao, H; Cao, X. Antitumor effects of interleukin-18 gene-modified hepatocyte cell line on implanted liver carcinoma.. Chinese medical journal. 2003-10, 116 (10): 1475–9 [2019-12-11]. PMID 14570604. 
  12. ^ Hisada, M; Kamiya, S; Fujita, K; Belladonna, ML; Aoki, T; Koyanagi, Y; Mizuguchi, J; Yoshimoto, T. Potent antitumor activity of interleukin-27.. Cancer research. 2004-02-01, 64 (3): 1152–6 [2019-12-11]. PMID 14871851. doi:10.1158/0008-5472.can-03-2084. 
  13. ^ Hisada, M; Yoshimoto, T; Kamiya, S; Magami, Y; Miyaji, H; Yoneto, T; Tamada, K; Aoki, T; Koyanagi, Y; Mizuguchi, J. Synergistic antitumor effect by coexpression of chemokine CCL21/SLC and costimulatory molecule LIGHT.. Cancer gene therapy. 2004-04, 11 (4): 280–8 [2019-12-11]. PMID 15002032. doi:10.1038/sj.cgt.7700676. 

外部链接

编辑
检索自“https://zh.wikipedia.org/w/index.php?title=C-26&oldid=70122837”